In addition, the diagnostic ability of our model and the SEPT9 model were both significantly affected by the KRAS mutation status in patients, and none of them achieved satisfactory sensitivities and specificities in the diagnosis of KRAS- CRC patients, suggesting that the mutation landscape of the patients should be taken into account to diagnose CRC accurately. This evidence concerns the gene KRAS and colorectal carcinoma.